KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 166 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: A double-blind, randomized, placebo-controlled study. PMID 36275698 · Front Immunol · 2022 The record is an original report of a randomized, double-blind, placebo-controlled Phase II trial (inferred from the context of a definitive study for a specific combination therapy) with drug intervention and key secondary time-to-event endpoints (PFS, OS) with formal results.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Is 5 the New 25? Long-Term Oncologic Outcomes From a Phase II, Prospective, 5-Fraction Preoperative Radiation Therapy Trial in Patients With Localized Soft Tissue Sarcoma. PMID 35647402 · Adv Radiat Oncol · 2022 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
B
影子组漏检补回 eligibleexplicit_phase3_randomized needs_review 1 Figure · 2 Panel · risk not_visible
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. PMID 34388377 · Cancer Cell · 2021-Sep-13 The record meets all required eligibility criteria: it is a phase 3, randomized, drug-intervention trial in human oncology (advanced NSCLC) with a primary time-to-event efficacy endpoint (PFS) and reports original results with a hazard ratio and Kaplan-Meier-derived PFS estimates.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohort. PMID 34371444 · Eur J Cancer · 2021-Sep Eligible. The record describes a long-term follow-up analysis of a Phase III randomized trial comparing adjuvant BEP chemotherapy vs. RPLND in stage I NSGCT, with RFS/OS endpoints. The publication type is explicitly 'Clinical Trial, Phase III', and the abstract reports randomized comparison and time-to-event outcomes. This meets all inclusion criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. PMID 34549539 · Cancer Med · 2021-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type confirmed 1 Figure · 6 Panel · risk visible
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. PMID 34048946 · J Thorac Oncol · 2021-Oct Five-year update of a randomized phase 3 trial with drug intervention and primary time-to-event efficacy endpoint (OS) meets all eligibility criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial. PMID 34846525 · JAMA Netw Open · 2021-Nov-01 The record describes a randomized clinical trial in oncology with a drug intervention, human subjects, and a primary time-to-event efficacy endpoint (DFS). The phase is not explicitly stated in the provided metadata (e.g., 'Phase III'), but the trial is described as a 'Randomized Clinical Trial' and is labeled as a 'Comparative Study' and 'Multicenter Study'. Given the context (large patient population, multicenter design, comparison of standard vs. intensified chemotherapy regimens in the adjuvant setting for advanced rectal cancer), it is functionally a definitive, Phase III-equivalent trial. The report presents original, primary results with Kaplan-Meier-derived DFS and OS data.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 2 Panel · risk visible
Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone - Additional data from a phase 3 trial. PMID 34560383 · Oral Oncol · 2021-Nov 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. PMID 34597366 · Blood Adv · 2021-Dec-28 The record describes a definitive randomized Phase III trial (ISRCTN40571019) evaluating quizartinib plus LDAC versus LDAC alone in older AML patients, with OS as a key time-to-event endpoint reported with HR and 95% CI, meeting all inclusion criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 1 Panel · risk visible
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. PMID 34709929 · J Clin Oncol · 2021-Dec-20 This is a final analysis report from the randomized Phase III CLL14 trial, presenting PFS (primary endpoint) and OS (key secondary endpoint) with HRs and Kaplan-Meier estimates, satisfying all eligibility criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. PMID 34914339 · N Engl J Med · 2021-Dec-16 The trial is a Phase III randomized controlled trial with drug intervention, human oncology, and primary time-to-event efficacy endpoints (iDFS, DRFS) reported with HRs and KM data. All required criteria are explicitly met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 6 Panel · risk visible
FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review. PMID 34301748 · Clin Cancer Res · 2021-Dec-15 The abstract describes a randomized trial (ADAURA) of osimertinib vs. placebo in surgically reected non-small cell lung cancer, with a primary time-to-event efficacy endpoint (DFS) and a drug-containing intervention. Although the trial phase is not explicitly stated in the abstract, the context of a definitive adjuvant therapy trial, the FDA approval based on its results, and the reported statistical magnitude (HR 0.20, P<0.0001) strongly indicate a Phase III trial. The record is an FDA approval summary summarizing the trial's primary results, not a post-hoc or secondary analysis.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials. PMID 34615722 · Clin Cancer Res · 2021-Dec-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Primary Surgery with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-year Follow-up; Protocol MF07-01 Randomized Clinical Trial. PMID 34530124 · J Am Coll Surg · 2021-Dec The record is from a randomized controlled trial (MF07-01) evaluating locoregional treatment plus systemic therapy versus systemic therapy alone in de novo stage IV breast cancer. The title and abstract confirm it is an oncology study in humans, randomized, with a primary time-to-event efficacy endpoint (overall survival) reported with hazard ratios and Kaplan-Meier survival percentages. The intervention includes systemic therapy (drug-containing), and the results represent the original 10-year final follow-up. Although the specific phase (e.g., Phase III) is not explicitly stated in the provided metadata, the study is a multicenter, randomized clinical trial with a definitive comparison and a conclusive primary endpoint result, which qualifies as a definitive phase for adjudication purposes.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. PMID 34152804 · J Clin Oncol · 2021-Aug-10 The record describes a large, randomized phase III trial with drug-containing interventions and primary time-to-event efficacy endpoints (EFS, OS). The trial phase is implicitly definitive (comparing standard-of-care regimens) and the report contains original primary results.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. PMID 34108261 · Mol Cancer Ther · 2021-Aug 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L B
旧查询独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed